ARCA believes that the AF burden endpoint can help provide an accurate and extensive assessment of each individual's AF episodes, and will be useful in evaluating the relative efficacies of Gencaro and metoprolol CR/XL. Beneath the collaboration, Medtronic will support the implantation and use of the Medtronic monitoring products, and can manage the AF burden data analysis and collection. If GENETIC-AF proceeds to Phase 3, the celebrations will seek to sign up at least 100 extra sufferers in the AF burden substudy. Dr. Michael Bristow, MD, PhD, President and Chief Executive Officer of ARCA, said, ‘We are worked up about our collaboration with Medtronic on GENETIC-AF. We believe that the usage of implanted, constant monitoring devices that enable the more exact measurement of atrial fibrillation represents the next generation of medical diagnosis and treatment plans for individuals at risk because of this disease.The addition of these compounds provides Vertex with multiple possibilities to develop potential, new, all-oral combination regimens for chronic hepatitis C. Vertex expects ALS-2200 and ALS-2158 to enter clinical development this year later. Related StoriesUC Irvine Health researchers develop one-step test to detect HCV infectionsNew vaccine candidate shows great promise at fighting respiratory syncytial virusDengue-infected individuals with few or no symptoms transmit virus to mosquitoes We are excited to begin working with Vertex, as we think that the Alios nucleotide analogues provide an important opportunity to improve patient treatment in hepatitis C, stated Lawrence M.